Cargando…
The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series
INTRODUCTION: Stroke-like syndrome (SLS) is a rare subacute neurological complication of intrathecal or high-dose (≥500 mg) Methotrexate (MTX) administration. Its clinical features, evoking acute cerebral ischaemia with fluctuating course symptoms and a possible spontaneous resolution, have elicited...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226576/ https://www.ncbi.nlm.nih.gov/pubmed/35756920 http://dx.doi.org/10.3389/fneur.2022.920214 |
_version_ | 1784733935038627840 |
---|---|
author | Santangelo, Andrea Bartolini, Emanuele Nuzzi, Giulia Foiadelli, Thomas Michev, Alexandre Mina, Tommaso Trambusti, Irene Fichera, Valeria Bonuccelli, Alice Massimetti, Gabriele Peroni, Diego G. De Marco, Emanuela Coccoli, Luca Luti, Laura Bernasconi, Sayla Nardi, Margherita Menconi, Maria Cristina Casazza, Gabriella Pruna, Dario Mura, Rosamaria Marra, Chiara Zama, Daniele Striano, Pasquale Cordelli, Duccio M. Battini, Roberta Orsini, Alessandro |
author_facet | Santangelo, Andrea Bartolini, Emanuele Nuzzi, Giulia Foiadelli, Thomas Michev, Alexandre Mina, Tommaso Trambusti, Irene Fichera, Valeria Bonuccelli, Alice Massimetti, Gabriele Peroni, Diego G. De Marco, Emanuela Coccoli, Luca Luti, Laura Bernasconi, Sayla Nardi, Margherita Menconi, Maria Cristina Casazza, Gabriella Pruna, Dario Mura, Rosamaria Marra, Chiara Zama, Daniele Striano, Pasquale Cordelli, Duccio M. Battini, Roberta Orsini, Alessandro |
author_sort | Santangelo, Andrea |
collection | PubMed |
description | INTRODUCTION: Stroke-like syndrome (SLS) is a rare subacute neurological complication of intrathecal or high-dose (≥500 mg) Methotrexate (MTX) administration. Its clinical features, evoking acute cerebral ischaemia with fluctuating course symptoms and a possible spontaneous resolution, have elicited interest among the scientific community. However, many issues are still open on the underlying pathogenesis, clinical, and therapeutic management and long-term outcome. MATERIALS AND METHODS: We retrospectively analyzed clinical, radiological and laboratory records of all patients diagnosed with SLS between 2011 and 2021 at 4 National referral centers for Pediatric Onco-Hematology. Patients with a latency period that was longer than 3 weeks between the last MTX administration of MTX and SLS onset were excluded from the analysis, as were those with unclear etiologies. We assessed symptom severity using a dedicated arbitrary scoring system. Eleven patients were included in the study. RESULTS: The underlying disease was acute lymphoblastic leukemia type B in 10/11 patients, while fibroblastic osteosarcoma was present in a single subject. The median age at diagnosis was 11 years (range 4–34), and 64% of the patients were women. Symptoms occurred after a mean of 9.45 days (± 0.75) since the last MTX administration and lasted between 1 and 96 h. Clinical features included hemiplegia and/or cranial nerves palsy, paraesthesia, movement or speech disorders, and seizure. All patients underwent neuroimaging studies (CT and/or MRI) and EEG. The scoring system revealed an average of 4.9 points (± 2.3), with a median of 5 points (maximum 20 points). We detected a linear correlation between the severity of the disease and age in male patients. CONCLUSIONS: SLS is a rare, well-characterized complication of MTX administration. Despite the small sample, we have been able to confirm some of the previous findings in literature. We also identified a linear correlation between age and severity of the disease, which could improve the future clinical management. |
format | Online Article Text |
id | pubmed-9226576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92265762022-06-25 The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series Santangelo, Andrea Bartolini, Emanuele Nuzzi, Giulia Foiadelli, Thomas Michev, Alexandre Mina, Tommaso Trambusti, Irene Fichera, Valeria Bonuccelli, Alice Massimetti, Gabriele Peroni, Diego G. De Marco, Emanuela Coccoli, Luca Luti, Laura Bernasconi, Sayla Nardi, Margherita Menconi, Maria Cristina Casazza, Gabriella Pruna, Dario Mura, Rosamaria Marra, Chiara Zama, Daniele Striano, Pasquale Cordelli, Duccio M. Battini, Roberta Orsini, Alessandro Front Neurol Neurology INTRODUCTION: Stroke-like syndrome (SLS) is a rare subacute neurological complication of intrathecal or high-dose (≥500 mg) Methotrexate (MTX) administration. Its clinical features, evoking acute cerebral ischaemia with fluctuating course symptoms and a possible spontaneous resolution, have elicited interest among the scientific community. However, many issues are still open on the underlying pathogenesis, clinical, and therapeutic management and long-term outcome. MATERIALS AND METHODS: We retrospectively analyzed clinical, radiological and laboratory records of all patients diagnosed with SLS between 2011 and 2021 at 4 National referral centers for Pediatric Onco-Hematology. Patients with a latency period that was longer than 3 weeks between the last MTX administration of MTX and SLS onset were excluded from the analysis, as were those with unclear etiologies. We assessed symptom severity using a dedicated arbitrary scoring system. Eleven patients were included in the study. RESULTS: The underlying disease was acute lymphoblastic leukemia type B in 10/11 patients, while fibroblastic osteosarcoma was present in a single subject. The median age at diagnosis was 11 years (range 4–34), and 64% of the patients were women. Symptoms occurred after a mean of 9.45 days (± 0.75) since the last MTX administration and lasted between 1 and 96 h. Clinical features included hemiplegia and/or cranial nerves palsy, paraesthesia, movement or speech disorders, and seizure. All patients underwent neuroimaging studies (CT and/or MRI) and EEG. The scoring system revealed an average of 4.9 points (± 2.3), with a median of 5 points (maximum 20 points). We detected a linear correlation between the severity of the disease and age in male patients. CONCLUSIONS: SLS is a rare, well-characterized complication of MTX administration. Despite the small sample, we have been able to confirm some of the previous findings in literature. We also identified a linear correlation between age and severity of the disease, which could improve the future clinical management. Frontiers Media S.A. 2022-06-10 /pmc/articles/PMC9226576/ /pubmed/35756920 http://dx.doi.org/10.3389/fneur.2022.920214 Text en Copyright © 2022 Santangelo, Bartolini, Nuzzi, Foiadelli, Michev, Mina, Trambusti, Fichera, Bonuccelli, Massimetti, Peroni, De Marco, Coccoli, Luti, Bernasconi, Nardi, Menconi, Casazza, Pruna, Mura, Marra, Zama, Striano, Cordelli, Battini and Orsini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Santangelo, Andrea Bartolini, Emanuele Nuzzi, Giulia Foiadelli, Thomas Michev, Alexandre Mina, Tommaso Trambusti, Irene Fichera, Valeria Bonuccelli, Alice Massimetti, Gabriele Peroni, Diego G. De Marco, Emanuela Coccoli, Luca Luti, Laura Bernasconi, Sayla Nardi, Margherita Menconi, Maria Cristina Casazza, Gabriella Pruna, Dario Mura, Rosamaria Marra, Chiara Zama, Daniele Striano, Pasquale Cordelli, Duccio M. Battini, Roberta Orsini, Alessandro The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series |
title | The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series |
title_full | The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series |
title_fullStr | The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series |
title_full_unstemmed | The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series |
title_short | The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series |
title_sort | clinical impact of methotrexate-induced stroke-like neurotoxicity in paediatric departments: an italian multi-centre case-series |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226576/ https://www.ncbi.nlm.nih.gov/pubmed/35756920 http://dx.doi.org/10.3389/fneur.2022.920214 |
work_keys_str_mv | AT santangeloandrea theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT bartoliniemanuele theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT nuzzigiulia theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT foiadellithomas theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT michevalexandre theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT minatommaso theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT trambustiirene theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT ficheravaleria theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT bonuccellialice theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT massimettigabriele theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT peronidiegog theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT demarcoemanuela theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT coccoliluca theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT lutilaura theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT bernasconisayla theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT nardimargherita theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT menconimariacristina theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT casazzagabriella theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT prunadario theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT murarosamaria theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT marrachiara theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT zamadaniele theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT strianopasquale theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT cordelliducciom theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT battiniroberta theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT orsinialessandro theclinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT santangeloandrea clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT bartoliniemanuele clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT nuzzigiulia clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT foiadellithomas clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT michevalexandre clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT minatommaso clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT trambustiirene clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT ficheravaleria clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT bonuccellialice clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT massimettigabriele clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT peronidiegog clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT demarcoemanuela clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT coccoliluca clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT lutilaura clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT bernasconisayla clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT nardimargherita clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT menconimariacristina clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT casazzagabriella clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT prunadario clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT murarosamaria clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT marrachiara clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT zamadaniele clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT strianopasquale clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT cordelliducciom clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT battiniroberta clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries AT orsinialessandro clinicalimpactofmethotrexateinducedstrokelikeneurotoxicityinpaediatricdepartmentsanitalianmulticentrecaseseries |